Augustine Therapeutics

About:

Augustine Therapeutics is discovering and developing innovative medicines for the treatment of neuromuscular and neurodegeneratives diseases

Website: https://www.augustinetx.com/

Top Investors: Eli Lilly, Asabys Partners, PMV, VIB, AdBio partners

Description:

Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors for the treatment of axonopathies such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair.

Total Funding Amount:

21.2M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Leuven, Vlaams-Brabant, Belgium

Founded Date:

2019-03-01

Contact Email:

contact(AT)augustinetx.com

Founders:

Bart De Strooper, Joris De Wit, Ludo Van den Bosh

Number of Employees:

1-10

Last Funding Date:

2024-06-26

IPO Status:

Private

Industries:

© 2025 bioDAO.ai